Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: UMLS:C0728731 (
prematurity
)
7,134
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
Neuroprotection is an unmet need in eye disorders characterized by retinal ganglion cell (RGC) death, such as
prematurity
-induced retinal degeneration, glaucoma, and age-related macular degeneration. In all these disorders excitotoxicity is a prominent component of neuronal damage, but clinical data discourage the development of NMDA receptor antagonists as neuroprotectants. Here, we show that activation of
mGlu1
metabotropic glutamate receptors largely contributes to excitotoxic degeneration of RGCs. Mice at postnatal day 9 were challenged with a toxic dose of monosodium glutamate (MSG, 3g/kg), which caused the death of >70% of Brn-3a
+
RGCs. Systemic administration of the
mGlu1
receptor negative allosteric modulator (NAM), JNJ16259685 (2.5mg/kg, s.c.), was largely protective against MSG-induced RGC death. This treatment did not cause changes in motor behavior in the pups. We also injected MSG to crv4 mice, which lack
mGlu1
receptors because of a recessive mutation of the gene encoding the
mGlu1
receptor. MSG did not cause retinal degeneration in crv4 mice, whereas it retained its toxic activity in their wild-type littermates. These findings demonstrate that
mGlu1
receptors play a key role in excitotoxic degeneration of RGCs, and encourage the study of
mGlu1
receptor NAMs in models of retinal neurodegeneration.
...
PMID:Permissive role for mGlu1 metabotropic glutamate receptors in excitotoxic retinal degeneration. 2891 54